Plain-English translation of NCT06180174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of cell therapy designed to treat B-cell lymphoma that has come back or stopped responding to standard chemotherapy. Researchers take your immune cells, engineer them in the lab to recognize and attack cancer cells, and give them back to you as a single infusion. The goal is to see if this approach is safe and effective for patients whose lymphoma has not responded to previous treatments.
Many patients with B-cell lymphoma eventually stop responding to standard chemotherapy and antibody treatments, leaving them with few options. This medication represents a newer approach that harnesses your own immune system to fight the cancer, potentially offering hope to people who have exhausted conventional therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will collect some of your blood cells and send them to a lab where they will be engineered over about 3 days. You will then receive a single infusion of these modified cells back into your body. The trial tests four different dose levels to find the safest and most effective amount, with your dose determined by when you enroll. You will be monitored closely afterward to see how you respond and to watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chongqing Precision Biotech Co., Ltd
Collaborators
Peking University Cancer Hospital & Institute
Enrollment target
~24 participants
Started
December 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuqin Song, M.D
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.